Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

bagholderzunite 14 posts  |  Last Activity: Jul 21, 2015 2:37 PM Member since: Mar 28, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Listening to FUD = Loss of your FUNDS

    by immunonc Jul 21, 2015 11:15 AM
    bagholderzunite bagholderzunite Jul 21, 2015 2:37 PM Flag

    Oh, you know, just surfing around, enjoying life, noticing paid pumpers controlling a board, pointing it out...

    Nothing big -- just that sort of thing. Thanks for asking!

  • Reply to

    Listening to FUD = Loss of your FUNDS

    by immunonc Jul 21, 2015 11:15 AM
    bagholderzunite bagholderzunite Jul 21, 2015 2:21 PM Flag

    Hey ryan!

    How's the pumping going?

    Isn't it great that you can delete all your messages after a pump is done, and move on to the next one?

    That's a really great feature here, don't you think?

    Enjoy your pumping (until it's over soon)!

    Regards,
    Bagz

  • bagholderzunite bagholderzunite Jul 17, 2015 3:28 PM Flag

    As a said awhile back, I'm not "saying" this, I'm copying it directly off the European trial registry website. All you have to do is read it:

    E.5 End points
    E.5.1 Primary end point(s) Time to objective demonstration of disease progression or death,
    measured from time of randomization (progression free survival, PFS),
    in patients with no evidence of disease progression after external beam
    radiation therapy with concurrent temozolomide chemotherapy.

    E.5.1.1 Timepoint(s) of evaluation of this end point The primary endpoint will be evaluated when 248 events of progression or death have occurred. in addition, two interim analyses will evaluate the endpoint when approximately 60% and 80% of the events have occurred.

    E.5.2 Secondary end point(s) Overall survival: In patients with no evidence of disease progression after external beam radiation therapy with concurrent temozolomide chemotherapy.

    E.5.2.1 Timepoint(s) of evaluation of this end point Overall survival will be assessed when 233 deaths have occurred.

  • bagholderzunite bagholderzunite Jul 17, 2015 9:55 AM Flag

    Buzzy, this is not correct. 248 events is the end of the trial. The interims are at 60% and 80% of 248.

    Regards,
    Bagz

  • bagholderzunite by bagholderzunite Jul 9, 2015 1:14 PM Flag

    Linda controls so much of the float that it's really hard to impact the price.

    I wonder how much of the published volume is really volume.

  • Reply to

    7/2/15 Form 4

    by oaksapollo Jul 9, 2015 9:15 AM
    bagholderzunite bagholderzunite Jul 9, 2015 11:55 AM Flag

    #$%$. SEC disclosure rules have nothing to do with GAAP accounting standards.

  • Reply to

    7/2/15 Form 4

    by oaksapollo Jul 9, 2015 9:15 AM
    bagholderzunite bagholderzunite Jul 9, 2015 11:53 AM Flag

    No Oak, I don't think that's right, technically. Cognate did give them NWBO shares, but it was shares they already had. Of course in the broader sense you're right -- Linda has piled up shares all over the place, effectively diluting longs like crazy, but in the narrow context of that recent Form 4, it wasn't NWBO (Linda) handing over appreciated shares, it was Cognate (Linda).

    Regards,
    Bagz

  • Reply to

    7/2/15 Form 4

    by oaksapollo Jul 9, 2015 9:15 AM
    bagholderzunite bagholderzunite Jul 9, 2015 11:31 AM Flag

    ryanlies:

    What are the rules then? What level of ownership creates control? What about different classes of stock, or derivative instruments like options or warrants? What about chains of ownership? Family members? What happens when those relationships change vis-a-vis existing positions?

    I think the whole board would benefit from your extensive knowledge on the topic.

    TIA,
    Bagz

  • Reply to

    7/2/15 Form 4

    by oaksapollo Jul 9, 2015 9:15 AM
    bagholderzunite bagholderzunite Jul 9, 2015 10:52 AM Flag

    By the way, ryanlies, you seem very familiar to me.

    Were you a GALE pumper as well? Pretty sure I remember you being over there before the pump busted.

  • Reply to

    7/2/15 Form 4

    by oaksapollo Jul 9, 2015 9:15 AM
    bagholderzunite bagholderzunite Jul 9, 2015 10:51 AM Flag

    The rules on that stuff are complicated, espeically with regard to offshore entities. Using chains of ownership or taking advantage of lax structural requirements in those jurisdictions permits all kinds of chicanery. It is perfectly possible that Linda effectively controls an offshore entity without technically controlling it from an SEC standpoint. This kind of thing is done ALL THE TIME in these small Nasdaq companies.

    I didn't say I knew 100% who the "unrelated party" was. I just said probably.

  • Reply to

    7/2/15 Form 4

    by oaksapollo Jul 9, 2015 9:15 AM
    bagholderzunite bagholderzunite Jul 9, 2015 10:23 AM Flag

    Meifud:

    The transfer of shares by Cognate to the "unrelated third party investor" (which is probably a Linda entity) counts as a "sale" from an SEC disclosure standpoint. That's how Cognate has to report it. The third party probably sold the shares. In my opinion, this is just Linda selling shares, because she is all of the entities -- it's just a shell game -- but that's just my opinion.

    Regards,
    Bagz

  • Reply to

    7/2/15 Form 4

    by oaksapollo Jul 9, 2015 9:15 AM
    bagholderzunite bagholderzunite Jul 9, 2015 10:16 AM Flag

    Yeah, although no way to be sure, the "unrelated third party investor" is probably one of the Toucan entities.

    Here's what's really fun about all of this:

    NWBO = Linda Powers
    Cognate = Linda Powers
    Toucan entities = Linda Powers

    You can have the most fun by substituting "Linda Powers" where you see anything related to those terms. For example:

    3. Linda Powers entered into two convertible loans, each in the amount of $2,500,000, to an Linda Powers in June and July, 2014, and provided the proceeds of the financings for Linda Powers' programs. The debt was secured by shares of Linda Powers owned by Linda Powers and was convertible, at Linda Powers' election, into Linda Powers common shares owned by Linda Powers at a fixed conversion price. Linda Powers elected to take repayment in Common Shares rather than in cash. Therefore, on June 30, 2015, Linda Powers transferred 1,118,092 Common Shares to settle the debt notes..

    I'm really surprised the SEC doesn't see this and ask all sorts of questions about arms-length dealing and other securities related issues. But they are really busy, to be fair. There are LOTS of situations like this in small Nasdaq companies.

    By the way... Aracaris Capital Ltd? The "subsidiary" of NWBO... look it up. Aracaris is a variety of toucan.

    Regards,
    Bagz

  • bagholderzunite bagholderzunite Jul 9, 2015 9:40 AM Flag

    There's also this:

    Secondary end point(s) Overall survival: In patients with no evidence of disease progression after external beam radiation therapy with concurrent temozolomide chemotherapy.

    E.5.2.1 Timepoint(s) of evaluation of this end point Overall survival will be assessed when 233 deaths have occurred.

    It's likely that 233 deaths occur after 248 progressions, so the trial will actually keep going for awhile after the primary endpoint is assessed (assuming they don't stop the trial early, which I think they will -- for futility).

    Regards,
    Bagz

  • bagholderzunite bagholderzunite Jul 9, 2015 9:20 AM Flag

    Buzzy:

    This is from the Euro (German) protocol summary on the Euro trial register:

    E.5.1.1 Timepoint(s) of evaluation of this end point The primary endpoint will be evaluated when 248 events of progression or death have occurred. in addition, two interim analyses will evaluate the endpoint when approximately 60% and 80% of the events have occurred.

    248 x 60% = 148.8 events
    248 x 80% = 198.4 events

    These are the interim triggers, I believe...248 events is the end ot the trial.

    Regards,
    Bagz

OGXI
3.51-0.09(-2.50%)Jul 28 4:00 PMEDT